Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 22 (oversold) · MACD below its signal · 5% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $406.8K | 0.00% | 73.30K | −18% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NERV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NERV.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.0 | 62.6 | -8.7 | 7.4 | -24.1 | 13.0 | -28.3 | 14.6 | -26.5 | -24.9 | −37.4% | ||
| 2025 | 4.0 | -27.7 | 1.8 | -1.8 | -7.8 | 11.7 | 8.7 | 26.2 | -10.8 | 99.5 | -0.5 | -3.8 | +80.9% |
| 2024 | 37.4 | -68.4 | -3.4 | -8.5 | 8.1 | 25.1 | -6.9 | -7.7 | -2.6 | -10.3 | -5.8 | -1.5 | −63.9% |
| 2023 | 50.3 | -9.6 | -25.9 | 75.0 | 113.2 | 53.1 | 4.0 | -12.0 | -17.6 | -30.1 | 62.9 | -21.7 | +286.8% |
| 2022 | 3.0 | -14.4 | 17.6 | -38.6 | -21.6 | 3.4 | -19.0 | 320.9 | -18.2 | -71.3 | 33.6 | -55.1 | −75.2% |
| 2021 | 36.3 | -2.8 | -5.8 | -18.5 | 23.9 | -21.4 | -20.7 | 0.0 | -5.4 | -19.5 | -30.6 | -17.5 | −65.8% |
| 2020 | 14.3 | -10.5 | -17.3 | 49.0 | -58.6 | -2.7 | -3.5 | -8.8 | 0.0 | 0.9 | 21.2 | -39.8 | −67.1% |
| 2019 | -2.4 | 20.5 | -0.9 | -6.2 | -29.3 | 8.1 | 17.9 | 7.5 | 8.5 | -38.8 | 31.9 | 13.8 | +5.5% |
| 2018 | 5.8 | -18.0 | 19.0 | 4.8 | 34.4 | -6.3 | -2.4 | 29.2 | 20.7 | -12.6 | -27.9 | -14.8 | +11.4% |
| 2017 | -9.8 | -17.5 | -7.4 | -6.2 | 8.6 | 7.3 | -24.9 | -9.0 | 25.6 | -17.1 | -8.7 | 5.2 | −48.5% |
| 2016 | -14.3 | -6.3 | 26.1 | 4.7 | 91.3 | -17.0 | 8.7 | 10.1 | 15.5 | -21.0 | 15.7 | -8.9 | +93.6% |
| 2015 | -27.2 | 17.4 | -2.7 | 1.4 | -0.8 | 15.3 | -1.1 | -2.7 | -5.9 | 0.6 | -4.9 | 20.9 | +0.8% |
| 2014 | 12.2 | -14.5 | -27.6 | 7.3 | 28.1 | −4.6% |
Buy / hold / sell counts
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.